Kayque Almeida dos Santos

Kayque Almeida dos Santos

Auto-generated profile, based on publicly available information

Kayque Almeida dos Santos

Center for Quality Control of Medicines and Related Products, Federal University of Pernambuco, Recife, PE, Brazil

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2016 in Frontiers in Pharmacology
Verified
Journal Article
Open access
JSJonas R. Sanches
Jonas R. Sanches
LFLucas Martins França
Lucas Martins França
VCVinicyus T. Chagas
Vinicyus T. Chagas
RGRenato S. Gaspar
Renato S. Gaspar
KSKayque A. dos Santos
Kayque A. dos Santos
APAntonio Marcus De Andrade Paes
Antonio Marcus De Andrade Paes
Syzygium cumini (L.) Skeels (Myrtaceae) has been traditionally used to treat a number of illnesses. Ethnopharmacological studies have particularly addressed antidiabetic and metabolic-related effects of extracts prepared from its different parts, especially seed and pulp-fruit, however there is a lack of studies on phytochemical profile and biological properties of its leaf. As there is considerable interest in bioactive compounds to treat metabolic syndrome and its clustered risk factors, we sought to characterize the metabolic effects of hydroethanolic extract of S. cumini leaf (HESc) on lean and monosodium L-glutamate (MSG)-induced obese rats. HPLC-MS/MS characterization of the HESc polyphenolic profile, at 254 nm, identified 15 compounds pertaining to hydrolysable tannin and flavanol subclasses. At 60 days of age, both groups were randomly assigned to receive HESc (500 mg/kg) or vehicle for 30 days. At the end of treatment, obese+HESc exhibited significantly lower body weight gain, body mass index, and white adipose tissue mass, compared to obese rats receiving vehicle. Obese rats treated with HESc showed a 2-fold increase in lipolytic activity in the periepididymal fat pad, as well as, brought triglyceride levels in serum, liver and skeletal muscle back to levels close those found in lean animals. Furthermore, HESc also improved hyperinsulinemia and insulin resistance in obese+HESc rats, which resulted in partial reversal of glucose intolerance, as compared to obese rats. HESc had no effect in lean rats. Assessment of ex vivo glucose-stimulated insulin secretion showed HESc potentiated pancreatic function in islets isolated from both lean and obese rats treated with HESc. In addition, HESc (10 – 1000 ug/mL) increased glucose stimulated insulin secretion from both isolated rat islets and INS-1E beta cells. These data demonstrate that S. cumini leaf improved peripheral insulin sensitivity via stimulating/modulating beta cell insulin release, which was associated with improvements in metabolic outcomes in MSG-induced obese rats.

17 October 2022 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
KSKayque Almeida dos Santos
Kayque Almeida dos Santos
LDLucas Danda
Lucas Danda
TOThaísa Cardoso de Oliveira
Thaísa Cardoso de Oliveira
JSJosé Lamartine Soares Sobrinho
José Lamartine Soares Sobrinho
MSMonica F. L. R. Soares
Monica F. L. R. Soares
Amorphous solid dispersions (ASDs) are a viable alternative to enhance the kinetic solubility of poorly water-soluble drugs. However, there is lack of discussion about the impact of drug loading on dissolution rate and drug diffusion across the membrane generated by supersaturation. So, it was obtained amorphous solid dispersions with nevirapine and polyvinylpyrrolidone K-30 by solvent evaporation method using different drug loadings (10%, 15% and 20% w/w). Thermal analysis, Fourier transform infrared spectroscopy and x-ray diffraction characterized the ASDs, indicating that there was a good miscibility between components which stabilized the drug in its amorphous state. The intermolecular interactions impacted on the ASDs in vitro performance, where they were evaluated to dissolution tests under different conditions and permeability studies. All amorphous systems had an increment in aqueous solubility compared to nevirapine alone, although 10% amorphous solid dispersion (SD 10) kept drug supersaturation at very high concentrations longer, preventing the drug recrystallization, having the greater drug flux on membranes and more intermolecular interactions among the components. Therefore, large quantities of the polymer are required for the stability of the amorphous drug, due to the increase in the number of intermolecular interactions.

1 June 2025 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
KSKayque Almeida dos Santos
Kayque Almeida dos Santos
LMLivia Maria Coelho de Carvalho Moreira
Livia Maria Coelho de Carvalho Moreira
JSJosé Lamartine Soares Sobrinho
José Lamartine Soares Sobrinho
MSMonica F. L. R. Soares
Monica F. L. R. Soares
Introduction: Human Immunodeficiency Virus (HIV) infection is still a major global problem, whose drug treatment consists of prophylactic prevention and antiretroviral combination therapy for better pharmacological efficacy and control of the circulating virus. However, there are still pharmacological problems that need to be overcome, such as low aqueous solubility of drugs, toxicity, and low patient adherence. Drug delivery technologies can be used to overcome these barriers. Objective: This review summarized the latest drug delivery systems for HIV treatment. Initially, an overview of the current therapy was presented, along with the problems it presents. Then, the latest drug delivery systems used to overcome the challenges imposed in conventional HIV therapy were discussed. Conclusion: This review examines innovative approaches for HIV treatment, where various drug delivery systems have shown significant advantages, such as high drug encapsulation, improved solubility, and enhanced bioavailability both in vitro and in vivo. Strategies like cyclodextrins, solid dispersions, microneedles, and nanoparticles are explored to address challenges in drug solubility, bioavailability, and administration routes. Despite progress, obstacles like limited clinical trials and industrial scalability hinder the widespread adoption of these formulations, emphasizing the need for further research and collaboration to optimize and ensure accessibility of innovative HIV therapies, mainly in regions where access to HIV treatment is scarce and remains a challenge.